In a new study, researchers at the Biodesign Institute explore a safe and simple treatment for one of the most devastating and perplexing afflictions: Alzheimer’s disease.Continue reading
Author Archive: AZBio
Rowpar Pharmaceuticals CEO Shares Insights in Chief Executive Magazine
Jim Ratcliff shares what is like expanding into China during a Trade War.Continue reading
GT Medical Technologies Announces Publication of Data Showing Company’s Targeted Therapy is Effective for Treating Recurrences of Common Type of Brain Tumor
FDA-Cleared GammaTile Therapy Offers New Option for Patients with Recurrent Meningiomas
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
- Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease
- Significantly Expands Phase III Assets with Six Expected Near-Term Product Launches, Representing Greater Than $15 Billion in Revenue Potential
- Registrational Trial Opportunities and Early-Stage Pipeline Position Combined Company for Sustained Leadership Underpinned by Cutting-Edge Technologies and Discovery Platforms
- Strong Combined Cash Flows, Enhanced Margins and EPS Accretion of Greater Than 40% in First Full Year
- Approximately $2.5 Billion of Expected Run-Rate Cost Synergies to Be Achieved by 2022
Xcellerate Biomedical Technologies Announces Half a Million Dollar Raise
Xcellerate Biomedical Technologies, a new company based in Phoenix, AZ, has announced its second round capital raise of $500k for its first line of products, BioXcellerator™ – a medical strength line of formulations sold exclusively through top dermatologists, plastic surgeons, orthopedists and OB/GYN doctors. Continue reading
FDA Releases Final Guidance on the Breakthrough Devices Program
On December 18, 2019, the FDA has issued a final guidance on its Breakthrough Devices Program, which is intended to provide patients and healthcare providers with timely access to medical devices for diagnosis and treatment of life-threatening or irreversibly debilitating conditions and diseases. Continue reading
Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative
Biomarker potentially could identify individuals at risk of developing T1DContinue reading
Applications Open for MedTech Innovator 2019
MedTech Innovator is the medical technology industry’s global showcase and accelerator for innovative medical device, digital health and diagnostic companies. Continue reading
HTG Establishes a French Subsidiary to Support Expanding Growth
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the formation of a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”) in November 2018. This entity is expected to further facilitate HTG’s ability to generate European product revenue and to improve its responsiveness to the needs of its growing customer base in Europe. In conjunction with the subsidiary formation, HTG has also created an application incubator laboratory in Sausheim, France, which is expected to accelerate additional product applications and to provide direct customer service to European accounts.Continue reading